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fo the Editor: The morbidity and mortality associated with
ardiovascular disease (CVD) has been steadily declining in indus-
rialized nations over recent decades due to innovations in tech-
ology and widespread access to health care; however, the preva-
ence of CVD is expected to increase 137% between 1990 and
020 for those living in low- and middle-income countries
LMIC). The increasing prevalence as well as a lack of financial
eans to address the associated morbidity will result in further
isparities between developed nations and LMIC (1). The gap in
edical treatment is clearly evident in the field of cardiac electro-
hysiology—specifically in device implantation. This study exam-
nes the safety and efficacy of post-mortem pacemaker donation
rom the U.S. to patients in LMIC.
From January 2008 to July 2008, a total of 50 pacemakers were
onated from Detroit metropolitan area funeral homes to World
edical Relief—a nonprofit charitable organization specializing in
elivery ofmedical equipment toLMIC.Of these devices, 18 (36%)were
ound to have battery life70%. One of the devices was excluded due to
isual defects in structural integrity of the lead terminals.
Informed consent was obtained from all patients’ families in order
o remove and donate the pacemakers post-mortem. Trained physi-
ians at World Medical Relief inspected and interrogated all pace-
akers to assess functionality and remove all patient identifiers. Only
acemakers with 70% battery life were incorporated into the study.
evices from patients with evidence of communicable infectious
isease or that were previously recalled were not accepted.
Devices included in the study were then prepared for steriliza-
ion. Pipe cleaners and other instruments were employed to ensure
hat all debris was removed, specifically at the lead insertion sites.
evices were then bathed with isopropyl alcohol and soaked
vernight in Asepti-zyme (Ecolab, St. Paul, Minnesota) at a
oncentration of 1:128. Pacemakers were wiped with 70% ethanol,
ir dried, packed in gas permeable envelopes, and decontaminated
ia an 8-h ethylene oxide gas sterilization protocol.
Twelve patients were selected for pacemaker implantation at the
niversity of Philippines-Philippine General Hospital utilizing
uidelines for standard of care during the period of September 2008
o December 2008. All patients underwent a detailed socioeconomic
valuation and were deemed financially incapable of procuring a
ermanent pacemaker.
Of the refurbished devices, 8 were implanted as single-chamber
evices while the remaining 4 were implanted as dual-chamber devices.
or all devices, new leads were purchased through third-party vendors.
The average age of recipients of refurbished pacemakers was
2  10 years (range 28 to 82 years), with 50% of recipients being
en. Eleven patients received their initial pacemaker while 1 patient
as undergoing elective replacement due to battery end of life.
ndications for pacemaker placement included complete heart block bn  10) and sick sinus syndrome (n  2). Three patients required
ransvenous pacing before device placement (Table 1).
There were no complications in the patients with refurbished
acemakers. All patients presented for follow-up at 1 week and 2
onths post-procedure. There were no deaths during this follow-up
eriod. Six patients continue to be monitored at the University of
hilippines-Philippine General Hospital, while 6 patients have been
eferred to their primary cardiologists for follow-up and monitoring.
In this study, we examined the feasibility and safety of post-
ortem pacemaker donation for underserved nations. In our
ohort of 12 patients, all refurbished devices were functioning
ppropriately within 2 months of implantation. Moreover, none of
he patients experienced procedural complications such as device
alfunction or pacemaker infection despite the fact that several
atients were higher risk due to temporary pacing before perma-
ent device implantation. We believe that post-mortem pacemaker
mplantation is a safe and effective method of delivering health care
o those in underserved countries such as the Philippines.
Urbanization, globalization, and increasing age have culminated in
n epidemiological evolution of CVD as the primary cause of death
lobally (2). Moreover, of the 17.5 million deaths worldwide attrib-
ted to CVD in 2005, 80% occurred in LMIC (3). Many of these
ountries lack the financial resources to address this epidemic of
VD. As a result, resources are often directed away from high-cost
reatment strategies such as implantable cardiac rhythm management
evices.
The argument for pacemaker reuse has been debated for decades
ithin national health care systems. Although the reuse of explanted
acemakers in the U.S. is restricted by the Food and Drug Admin-
stration, countries such as Canada and Sweden have published
eports highlighting the clinical safety and efficacy of reimplantation
4–6). The 2002 American College of Cardiology/American Heart
ssociation/North American Society of Pacing and Electrophysiol-
gy Guideline Update for Implantation of Cardiac Pacemakers even
cknowledges that pacemaker reuse “may eventually add significantly
o the cost-effectiveness of cardiac pacing” (7).
In light of the widening health care disparity seen between the
ndustrialized world and developing nations, we feel that pace-
aker reuse is an ethical obligation to address the medical needs
or those who could not afford therapy otherwise. In accordance
ith previous studies, our data re-emphasizes that post-mortem
acemaker donation is a safe and effective method of alleviating the
orbidity associated with CVD in many individuals. Ongoing
esearch is necessary to evaluate the feasibility of regional and
otentially nationwide pacemaker donation programs in order to
urther alleviate the morbidity and mortality of symptomatic
radyarrhythmia seen in underprivileged nations.
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linical Characteristics of Patients Receiving Refurbished PacemakersTable 1 Clinical Characteristics of Patients Receiving Refurbished Pace
Patient # Age (Yrs) Sex
Pacemaker
Indication Clinical Sympto
1 68 M Sick sinus syndrome Syncope
2 74 M Third-degree block Dyspnea
3 70 M Sick sinus syndrome Pre-syncope
4 28 F Third-degree block Syncope
5 76 F Third-degree block Syncope
6 47 F Third-degree block Syncope
7 65 F Third-degree block Syncope
8 55 M Third-degree block Syncope
9 60 F Third-degree block Syncope
10 61 M Third-degree block Syncope
11 55 F Third-degree block Syncope
12 82 F Third-degree block Syncope
Required transvenous pacing before device placement; †patient had syncopal episodes for 1 year
emained in hospital for 15 days with transvenous pacemaker while waiting for procurement of dhe right ventricular outflow tract (RVOT)/subtricuspid region,
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Device
Manufacturer
Single Versus
Dual Chamber Complications Notable Events
Medtronic Single None —
St. Jude Medical Dual None —
Biotronik Dual None —
Medtronic Single None —
Medtronic Single None *†
Medtronic Single None ‡
St. Jude Medical Single None *§
St. Jude Medical Single None †
St. Jude Medical Dual None —
St. Jude Medical Dual None —
St. Jude Medical Single None †
Biotronik Single None *
device placement; ‡device was placed due to end of battery life on previous pacemaker; §patienterved as a consultant to Ablation Frontiers; and has received research grants from St.
ude Medical, Inc. and Boston Scientific.
Key Words: pacemaker reuse y health care disparity y low- and
middle-income countries.
Letters to the Editorhe Right Ventricular Outflow
ract in Arrhythmogenic Right
entricular Cardiomyopathy
alal et al. (1) describe the accordion sign in family members
f arrhythmogenic right ventricular dysplasia/cardiomyopathy
ARVD/C) probands as a promising tool for the early diagnosis of
he disease. Besides this qualitative feature, which also was seen inhey also mention that quantitative right ventricular parameters
ended to be abnormal in those with 1 criteria point in their
eclassified approach. However, they do not mention whether the
VOT was enlarged in this cohort, a fact we find surprising
ecause in a previous study (2) from the same group, 66% of
atients with ARVD/C had an enlarged RVOT measured on
tandard axial images.
Given the fact that Corrado et al. (3) have suggested that an
arly/minor form of ARVD/C may primarily involve the RVOT,
imicking idiopathic RVOT tachycardia, we believe that quanti-make
msative assessment of the RVOT should always be part of the
